YOLFTbeta
IVIM Technology, Inc

IVIM Technology, Inc

460470 · KQ · Healthcare / Medical Devices

2,340.00KRW-90.00 (-3.70%)

Price History

Full chart

Market Stats

Previous Close2,430.00
Open2,410.00
Day Range2,340.00 – 2,435.00
52-Week Range2,415.00 – 4,945.00
Volume11.35K
Market Cap44.90B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.88
50-Day Avg2,841.60
200-Day Avg3,253.45

About

IVIM Technology, Inc. develops intravital microscopy (IVM) platform. Its products include IVM-C3, a system for simultaneously observing various multi-cellular behaviors in small live animal models; IVM-M3, a system for users who need to conduct deeper-tissue imaging using less-scattering NIR wavelength; IVM-CMS3 for intravital functional imaging; IVM-CM3 that provides three-dimensional imaging of living cells near the skin or deep into the tumor in small animals; IVM-MS3 for in vivo imaging; and IVM-customized products. The company also provides preclinical contract research organization services. Its products are used in live cell intravital imaging, repetitive intravital imaging, in vivo drug efficacy monitoring, in vivo drug delivery monitoring, and ex vivo imaging applications. The company was founded in 2017 and is based in Daejeon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEODr. Pilhan Kim
  • Employees0
  • Headquarters#B-415, Daedeok BizCenter 17, Daejeon, South Korea, 34013, Korea
  • Websitehttps://www.ivimtech.com

Leadership

  • Dr. Pilhan KimChief Executive Officer · b. 1978

Financials

Income Statement

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue526.97M1.34B4.50B3.56B4.38B
Growth (%)-+153.88%+235.98%-20.71%+22.77%
Cost of Revenue649.92M1.18B3.07B2.22B3.15B
Gross Profit-122.94M159.57M1.43B1.35B1.23B
Gross Margin-23.33%11.93%31.70%37.77%28.12%
Operating Expense2.54B3.55B4.31B5.65B5.38B
Operating Income-2.66B-3.39B-2.89B-4.30B-4.15B
Operating Margin-504.48%-253.22%-64.21%-120.68%-94.91%
EBITDA--6.78B-2.33B-2.44B-1.79B
EBITDA Margin--506.93%-51.85%-68.53%-40.90%
Net Income-2.62B-9.74B-5.04B-4.00B-3.80B
Net Income Margin-497.27%-727.66%-112.20%-112.32%-86.90%
R&D526.69M567.73M261.84M704.29M693.13M
R&D as % of Total Revenue99.95%42.43%5.83%19.76%15.84%
Interest Expense1.15B2.09B1.61B184.48M160.58M
Interest Expense % of Total Revenue218.65%156.24%35.74%5.18%3.67%

Balance Sheet

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets6.95B19.15B16.53B34.89B30.23B
Total Liabilities17.37B39.16B3.71B3.61B2.59B
Total Equity-10.42B-20.02B12.82B31.27B27.64B
Cash1.36B992.63M3.56B2.45B3.21B
Net Debt141.51M507.37M---

Cash Flow

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.53B-4.08B-3.45B-6.93B-4.25B
Investing Cash Flow--11.08B6.17B-16.05B-
Financing Cash Flow-14.81B-149.72M21.85B-
Capital Expenditure1.39B422.20M496.04M663.93M2.48B
Free Cash Flow-4.92B-4.50B-3.94B-7.59B-6.73B
FCF to OCF139.43%110.34%114.39%109.58%158.40%

Earnings

Report DateSep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------
EPS Actual-107.04-8.21-93.36-78.69-38.99-41.01-89.97-7.55
Surprise--------
Timing--------

Key Statistics & Ratios

Market Cap44.90B
Enterprise Value26.40B
Trailing P/E0.00
Forward P/E0.00
Price / Sales6.85
Price / Book1.50
Revenue (TTM)6.56B
Gross Profit (TTM)2.12B
EBITDA-1.13B
Profit Margin-40.89%
Operating Margin-6.56%
Return on Equity-9.76%
Return on Assets-6.36%
Shares Outstanding15.12M
Shares Float9.60M
Beta0.88
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%